(2023). Urinary Neutrophil Gelatinase Associated lipocalin (NGAL) as A Biomarker of Acute Kidney Injury in Patients with Liver Cirrhosis. The Egyptian Journal of Hospital Medicine, 92(1), 6432-6439. doi: 10.21608/ejhm.2023.314507
. "Urinary Neutrophil Gelatinase Associated lipocalin (NGAL) as A Biomarker of Acute Kidney Injury in Patients with Liver Cirrhosis". The Egyptian Journal of Hospital Medicine, 92, 1, 2023, 6432-6439. doi: 10.21608/ejhm.2023.314507
(2023). 'Urinary Neutrophil Gelatinase Associated lipocalin (NGAL) as A Biomarker of Acute Kidney Injury in Patients with Liver Cirrhosis', The Egyptian Journal of Hospital Medicine, 92(1), pp. 6432-6439. doi: 10.21608/ejhm.2023.314507
Urinary Neutrophil Gelatinase Associated lipocalin (NGAL) as A Biomarker of Acute Kidney Injury in Patients with Liver Cirrhosis. The Egyptian Journal of Hospital Medicine, 2023; 92(1): 6432-6439. doi: 10.21608/ejhm.2023.314507
Urinary Neutrophil Gelatinase Associated lipocalin (NGAL) as A Biomarker of Acute Kidney Injury in Patients with Liver Cirrhosis
Background: The severity of acute kidney injury (AKI) syndrome varies. The blood urea nitrogen (BUN) and creatinine (Cr) retention, as well as a rapid drop in the glomerular filtration rate (GFR), are its defining features. The discovery of a superior gold standard to serum Cr concentration or urine output, as well as proof that a marker-directed therapy strategy may enhance clinical outcomes, would be significant step forward for AKI biomarker research. Objective: To determine if urine neutrophil gelatinase associated lipocalin (uNGAL) is a reliable indicator of AKI in patients with liver cirrhosis. Patients and methods: This study included 80 cirrhotic patients. Patients were allocated into two groups as follows: group I: 30 cirrhotic cases with normal kidney functions (without AKI) and group II: 50 cirrhotic cases with AKI who were divided into 3 subgroups according to type of AKI: group IIa included 20 cases with prerenal AKI, group IIb included 20 cases with hepatorenal syndrome (HRS-AKI) and group IIc included 10 cases with acute tubular necrosis (ATN). Results: In terms of uNGAL, there were statistically significant variations across the groups that were examined (P value <0.001) with mean uNGAL value is highest in group IIc (ATN) (259.80±44.364 ng/ml) followed by group IIb (HRS-AKI) (192.85±40.782 ng/ml) than group IIa (Pre-renal AKI) (61.00±8.706 ng/ml) and group I (29.00±5.420 ng/ml). uNGAL at a cut-off value ≥239 ng/ml could differentiate ATN from HRS with sensitivity of 80%, 90% specificity, 80% PPV, 90% NPV, with an area under curve (AUC) = 0.880, and P value of ˂ 0.001. uNGAL at cut-off value >190 ng/ml had 100% sensitivity, 88.24% specificity, 60% PPV, and 100% NPV for predicting inhospital mortality in cirrhotic patients with AKI (AUC = 0.96; P ˂ 0.001). Conclusion: To diagnose and differentiate between various causes of AKI in cases with liver cirrhosis, uNGAL may be employed as an accurate biomarker. Additionally, it has prognostic value in such patients.
View on SCiNiTO
Top